Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirabrutinib Maintenance Versus Placebo in Patients With Primary Central Nervous System Lymphoma in Complete Remission
NCT06940791Phase 2Recruiting
- Sponsor
- Kyorin University
- Start
- Oct 2023
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tirabrutinib in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Kyorin University. Primary endpoint: Progression-Free Survival based on independent review committee assessment up to 78 months. Started Oct 2023; status: recruiting.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06940791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940791.